September is Ovarian Cancer Awareness Month. Ovarian cancer is often called the silent killer because it presents with symptoms so subtle that women are told it’s aging, stress, or perimenopause. By the time it’s diagnosed, it’s often advanced. The tragedy is that we have biomarkers that can change this story, but they’re not routinely ordered.
This session covers what standard of care currently offers for ovarian and reproductive health assessment, what emerging research supports as the new standard, and why the gap exists. We’ll walk through markers you may have never heard of that leading practitioners are already using, and the specific questions to bring to your gynecologist or primary care physician. Ovarian health is not only about cancer detection. It’s about understanding what your hormones, your cycle history, and your family history mean for the decisions ahead of you.
Standard of care markers we’ll cover include CA-125, transvaginal ultrasound protocols, and standard hormonal panels. Emerging markers include HE4, ROMA index calculation, AMH interpretation in midlife, and the case for BRCA and Lynch syndrome genetic screening beyond family history criteria.
You’ll leave with a list of the exact questions to bring to your physician, understanding of what each marker measures and why, and the framework to make informed decisions about your ovarian and reproductive health going forward.